Want to see PVLA full AI Analyst Report?
PVLA Stock Chart & Stats
$148.24
$3.76(2.72%)
At close: 4:00 PM EDT
$148.24
$3.76(2.72%)
Day’s Range― - ―
52-Week Range$65.93 - $161.38
Previous Close$141.77
Volume173.59K
Average Volume (3M)213.37K
Market Cap
$2.00B
Enterprise Value$1.97B
Total Cash (Recent Filing)$250.58M
Total Debt (Recent Filing)$535.00K
Price to Earnings (P/E)―
Beta0.27
Next Earnings
Nov 17, 2026EPS Estimate
-1.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.83
Shares Outstanding14,408,407
10 Day Avg. Volume235,661
30 Day Avg. Volume213,373
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)42.09
Price to Sales (P/S)0.00
P/FCF Ratio-47.10
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-39.32
Forecast
1Y Price Target
$235.22Price Target Upside58.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-6.56
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Phase III EfficacyThe strong Phase III result provides clinical validation for QTORIN rapamycin in a serious rare disease with limited treatment options. Broad endpoint success and a high responder rate can support regulatory approval, physician adoption, and a durable commercial foundation if confirmed through the NDA process.
Regulatory Momentum Toward ApprovalRolling review and an already-submitted NDA module indicate meaningful progress toward commercialization and reduce the distance to a potential first product launch. A successful filing and approval would transition Palvella from development-stage operations toward recurring product revenue and a more scalable business model.
Cash Resources Support ExecutionThe enlarged cash position gives Palvella resources to complete regulatory work, fund launch preparation, and advance its pipeline over the next several quarters. Very low leverage further reduces balance-sheet pressure, providing greater flexibility while the company works toward potential commercialization.
Bears Say
No Current Commercial RevenuePalvella currently lacks established product revenue and remains dependent on research progress and eventual regulatory approval to create operating income. Persistent large losses limit earnings visibility and mean the company cannot yet demonstrate commercial demand, pricing realization, or sustainable profitability.
Persistent Cash BurnOngoing negative operating and free cash flow requires Palvella to consume its cash resources to fund development and operations. Even with substantial liquidity, prolonged burn can reduce financial flexibility and may require additional financing before the company generates recurring commercial cash flow.
Long Timelines For Pipeline ExpansionThe broader pipeline may expand the opportunity, but meaningful contributions from additional indications remain several years away and depend on further pivotal studies. This leaves near-term value concentrated in the initial microcystic LM program and exposes growth plans to clinical, regulatory, and execution delays.
Palvella Therapeutics News
PVLA FAQ
What was Palvella Therapeutics’s price range in the past 12 months?
Palvella Therapeutics lowest stock price was $65.93 and its highest was $161.38 in the past 12 months.
What is Palvella Therapeutics’s market cap?
Palvella Therapeutics’s market cap is $2.00B.
When is Palvella Therapeutics’s upcoming earnings report date?
Palvella Therapeutics’s upcoming earnings report date is Nov 17, 2026 which is in 37 days.
How were Palvella Therapeutics’s earnings last quarter?
Palvella Therapeutics released its earnings results on Aug 04, 2026. The company reported -$1.52 earnings per share for the quarter, missing the consensus estimate of -$1.173 by -$0.347.
Is Palvella Therapeutics overvalued?
According to Wall Street analysts Palvella Therapeutics’s price is currently Undervalued.
Does Palvella Therapeutics pay dividends?
Palvella Therapeutics does not currently pay dividends.
What is Palvella Therapeutics’s EPS estimate?
Palvella Therapeutics’s EPS estimate is -1.8.
How many shares outstanding does Palvella Therapeutics have?
Palvella Therapeutics has 14,408,407 shares outstanding.
What happened to Palvella Therapeutics’s price movement after its last earnings report?
Palvella Therapeutics reported an EPS of -$1.52 in its last earnings report, missing expectations of -$1.173. Following the earnings report the stock price went up 7.963%.
Which hedge fund is a major shareholder of Palvella Therapeutics?
Currently, no hedge funds are holding shares in PVLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Palvella Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$235.22 (58.68% Upside)
$235.22 (58.68% Upside)
Blogger Sentiment
Bullish
PVLA Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 70.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $49.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.2%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
97.98%
12-Months-Change
Fundamentals
Return on Equity
-47.84%
Trailing 12-Months
Asset Growth
243.76%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Palvella Therapeutics
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
PVLA Company Deck
PVLA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights substantial clinical and regulatory progress—compelling Phase III SELVA results (95% improvement on primary endpoint), rolling review and first NDA module submission—supported by strong financial resources (~$251M cash) and accelerated commercial hiring (≈40 reps). Near-term risks include the need to complete the NDA, initial lack of Breakthrough for cVM (to be addressed with additional 24‑week data and qualitative evidence), increased 2026 cash spend to accelerate launch readiness, and multi-year timelines to expand indications beyond microcystic LMs. Overall, the positive clinical data, regulatory momentum, funding and clear commercial plan meaningfully outweigh the challenges and remaining execution risks.View all PVLA earnings summariesPVLA Stock 12 Month Forecast
Average Price Target
$235.22
▲(58.68% Upside)
Technical Analysis
Ownership Overview
1.59% Insiders
20.71% Mutual Funds
57.05% Other Institutional Investors
8.69% Public Companies and
Individual Investors